Loading stock data…
AKBA
$0.92-0.02 (-1.67%)
After Hours$0.92+0.00 (+0.00%)· Last close Jun 9
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Akebia Therapeutics, Inc. in the Healthcare sector is trading at $0.92. Wall Street consensus targets $4.20 (5 analysts), implying a +354.3% move over the next 12 months. The stock is currently near its 52-week low of $0.88, remaining 48.1% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +354.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$0.92
Potential Downside
0%
Whystock Fair Value$0.92
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hy...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-74.93%
Volume
Today's trading volume
2.04M
Recent News
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near
Akebia Therapeutics (NASDAQ:AKBA) outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a fireside chat at the Jefferies 2026 Global Healthcare Conference. Erik, Akebia’s chief financial offic
Promising Penny Stocks To Consider In May 2026
The United States market has shown robust performance, with a 1.2% increase over the last week and a substantial 29% rise over the past year, alongside an optimistic forecast for earnings growth of 17% annually. In light of these conditions, investors might find opportunity in stocks that balance affordability with potential growth, particularly those often labeled as penny stocks. While the term may seem outdated, these smaller or newer companies can offer intriguing prospects when backed by...
Analysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter Results
One of the biggest stories of last week was how Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares plunged 23% in the...
Akebia (AKBA) Q1 2026 Earnings Transcript
Second, continue to build the clinical evidence to make Vafseo standard of care for patients on dialysis; and third, execute on our impressive kidney disease-focused clinical development pipeline. Earlier in Q1, at the Annual Dialysis Conference, we presented an economic analysis on the cost of hospitalizations for patients treated with Vadadustat versus darbepoetin.
Akebia Therapeutics Q1 Earnings Call Highlights
Akebia Therapeutics (NASDAQ:AKBA) executives highlighted a “strong start” to 2026 on the company’s first-quarter earnings call, pointing to record quarterly net product revenue for its anemia drug Vafseo, expanding use of observed dosing protocols at dialysis organizations, and continued progress ac